{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:50:04Z","timestamp":1760953804356,"version":"build-2065373602"},"reference-count":58,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T00:00:00Z","timestamp":1389657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>In an era of personalized medicine, disease specific biomarkers play an increasing role in the stratification of high-risk patient groups. Cutaneous malignant melanoma is the most deadly form of skin cancer with an ever-increasing global incidence, especially in patients under 35-years of age. Despite the excellent prognosis for patients diagnosed with early stage disease, metastatic disease still carries significant overall mortality. Biomarkers aim not only to identify high-risk patients, but also to provide potential therapeutic targets for differing patient subgroups. Furthermore, accessibility to tissue samples from a range of disease stages in malignant melanoma, unlike most other solid tissue tumours, provides the unique opportunity to explore the biology of tumour progression that may be relevant in the biology of cancer as a whole. Over the past decade, there have been major advances in targeted therapies, providing new avenues and hope to patients with this devastating disease. This review will focus on most up to date histological, serological and molecular biomarkers in malignant melanoma.<\/jats:p>","DOI":"10.3390\/healthcare2010060","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T11:21:38Z","timestamp":1389698498000},"page":"60-73","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Established and Emerging Biomarkers in Cutaneous  Malignant Melanoma"],"prefix":"10.3390","volume":"2","author":[{"given":"Stamatina","family":"Verykiou","sequence":"first","affiliation":[{"name":"Dermatological Sciences, Institute of Cellular Medicine, Newcastle University,  Newcastle upon Tyne, NE2 4HH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ellis","sequence":"additional","affiliation":[{"name":"Dermatological Sciences, Institute of Cellular Medicine, Newcastle University,  Newcastle upon Tyne, NE2 4HH, UK"},{"name":"The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust,  Middlesbrough, TS4 3BW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny","family":"Lovat","sequence":"additional","affiliation":[{"name":"Dermatological Sciences, Institute of Cellular Medicine, Newcastle University,  Newcastle upon Tyne, NE2 4HH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2014,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/annonc\/mdp251","article-title":"Biomarkers in melanoma","volume":"20","author":"Gogas","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2010.149","article-title":"Biomarkers: The useful and not so useful\u2014An assessment of molecular prognostic markers for cutaneous melanoma","volume":"130","author":"Rimm","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma","volume":"17","author":"Ellerhorst","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djp038","article-title":"Tissue biomarkers for prognosis in cutaneous melanoma: A systematic review and meta-analysis","volume":"101","author":"Bracken","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1200\/JCO.2005.04.3778","article-title":"Standards for reporting prognostic tumor marker studies","volume":"23","author":"Alonzo","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_8","first-page":"87","article-title":"The biology of melanoma prognostic factors","volume":"10","author":"Spatz","year":"2010","journal-title":"Discov. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","article-title":"Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma","volume":"172","author":"Breslow","year":"1970","journal-title":"Ann. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b vs. observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1200\/jco.2009.27.15_suppl.9007","article-title":"Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients","volume":"27","author":"Eggermont","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1245\/ASO.2005.04.027","article-title":"Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas","volume":"12","author":"Kesmodel","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1245\/ASO.2004.07.014","article-title":"The prognostic importance of tumor mitotic rate confirmed in 1,317 patients with primary cutaneous melanoma and long follow-up","volume":"11","author":"Francken","year":"2004","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2133.2009.09324.x","article-title":"Predicting outcome in melanoma: Where are we now?","volume":"161","author":"Jennings","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/1097-0142(19931115)72:10<3091::AID-CNCR2820721034>3.0.CO;2-V","article-title":"Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis","volume":"72","author":"Sirott","year":"1993","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjd.12088","article-title":"The challenge of developing useful blood-based biomarkers in melanoma","volume":"168","author":"Sullivan","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1097-0142(19900815)66:4<765::AID-CNCR2820660428>3.0.CO;2-M","article-title":"Immunohistochemical study of melanocytic naevus and malignant melanoma with monoclonal antibodies against S-100 subunits","volume":"66","author":"Cho","year":"1990","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1365-2133.1999.02905.x","article-title":"Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and\/or immunotherapy","volume":"40","author":"Hauschild","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y","article-title":"In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers","volume":"187","author":"Bosserhoff","year":"1999","journal-title":"J. Pathol."},{"key":"ref_21","first-page":"3149","article-title":"Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma","volume":"57","author":"Bosserhoff","year":"1997","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","article-title":"Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival","volume":"19","author":"Ugurel","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1479-5876-10-155","article-title":"Serum microRNAs as biomarkers for recurrence in melanoma","volume":"10","author":"Friedman","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/jid.2012.477","article-title":"Plasma MicroRNA-21 is associated with tumor burden in cutaneous melanoma","volume":"133","author":"Saldanha","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0140-6736(91)92100-G","article-title":"Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction","volume":"338","author":"Smith","year":"1991","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/CCLM.2009.009","article-title":"Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: Methodological pitfalls and clinical relevance","volume":"47","author":"Nezos","year":"2009","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/jid.2012.468","article-title":"Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma","volume":"133","author":"Khoja","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/jid.2013.34","article-title":"Circulating melanoma cells as a predictive biomarker","volume":"133","author":"Karakousis","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjd.12057","article-title":"Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression","volume":"168","author":"Reid","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.009","article-title":"Testing the cancer stem cell hypothesis in melanoma: The clinics will tell","volume":"338","author":"Shakhova","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/labinvest.2011.50","article-title":"Melanoma stem cells: Not rare, but well done","volume":"91","author":"Girouard","year":"2011","journal-title":"Lab. Invest."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","article-title":"A tumorigenic subpopulation with stem cell properties in melanomas","volume":"65","author":"Fang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ejca.2007.01.017","article-title":"Melanoma contains CD133 and ABCG2 positive cells with enhanced tumorigenic potential","volume":"43","author":"Monzani","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","article-title":"Identification of cells initiating human melanomas","volume":"451","author":"Schatton","year":"2008","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12015-008-9048-7","article-title":"Cancer Stem cells: A lesson from melanoma","volume":"5","year":"2009","journal-title":"Stem Cell Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/modpathol.3800720","article-title":"Increased expression of stem cell markers in malignant melanoma","volume":"20","author":"Klein","year":"2007","journal-title":"Modern Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e15183","DOI":"10.1371\/journal.pone.0015183","article-title":"CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells","volume":"5","author":"Taghizadeh","year":"2010","journal-title":"PLoS One"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1038\/onc.2011.656","article-title":"Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation","volume":"31","author":"Kumar","year":"2012","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/jnci\/djj103","article-title":"Gene expression profiling of primary cutaneous melanoma and clinical outcome","volume":"98","author":"Winnepenninckx","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bjc.6603028","article-title":"Metallothionein\u2014Overexpression as a highly significant prognostic factor in melanoma: A prospective study on 1,270 patients","volume":"94","author":"Weinlich","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/S0002-9440(10)64328-3","article-title":"Tumor lymphangiogenesis, a novel prognostic indicator for cutaneous melanoma metastasis and survival","volume":"162","author":"Dadras","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1600-0560.2008.01166.x","article-title":"Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis","volume":"36","author":"Doeden","year":"2009","journal-title":"J Cutan. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/jid.2008.347","article-title":"MicroRNA expression in melanocytic nevi: The usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling","volume":"129","author":"Glud","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/labinvest.2012.119","article-title":"In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor MicroRNA","volume":"92","author":"Hanna","year":"2012","journal-title":"Lab. Invest."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e72699","DOI":"10.1371\/journal.pone.0072699","article-title":"In-depth characterization of microRNA transcriptome in melanoma","volume":"8","author":"Kozubek","year":"2013","journal-title":"PLoS One"},{"key":"ref_50","first-page":"5012","article-title":"Micropthalmia transcription factor: A new prognostic marker in intermediate-thickness cutaneous malignant melanoma","volume":"60","author":"Salti","year":"2000","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdm545","article-title":"HSP90 as a marker of progression in melanoma","volume":"19","author":"McCarthy","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-04-1887","article-title":"Castello expression of CXCR4 predicts poor prognosis in patients with malignant melanoma","volume":"11","author":"Scala","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00008390-200310000-00008","article-title":"Hypoxia-inducible factors 1\u03b1 and 2\u03b1 are related to vascular endothelial growth factor expression and a poor prognosis in nodular malignant melanomas of the skin","volume":"13","author":"Giatromanolaki","year":"2003","journal-title":"Melanoma Res."},{"key":"ref_54","first-page":"17","article-title":"The stem cell marker nestin predicts poor prognosis in human melanoma","volume":"23","author":"Piras","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/jid.2013.197","article-title":"Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis","volume":"133","author":"Raskin","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.humpath.2011.05.008","article-title":"Neuropilin-2: A novel biomarker for malignant melanoma?","volume":"43","author":"Rushing","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1200\/JCO.2006.07.3833","article-title":"Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma","volume":"24","author":"Rangel","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0002-9440(10)64922-X","article-title":"Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor\/fibroblast growth factor receptor-1 and ephrin-A1\/EphA2 on melanoma progression","volume":"160","author":"Straume","year":"2002","journal-title":"Am. J. Pathol."}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/2\/1\/60\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:07:20Z","timestamp":1760216840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/2\/1\/60"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,14]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,3]]}},"alternative-id":["healthcare2010060"],"URL":"https:\/\/doi.org\/10.3390\/healthcare2010060","relation":{},"ISSN":["2227-9032"],"issn-type":[{"type":"electronic","value":"2227-9032"}],"subject":[],"published":{"date-parts":[[2014,1,14]]}}}